Analysts Expect Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) Will Post Earnings of -$0.29 Per Share

Wall Street analysts expect that Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) will report earnings of ($0.29) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Oramed Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.23) and the lowest estimate coming in at ($0.34). Oramed Pharmaceuticals reported earnings of ($0.18) per share in the same quarter last year, which suggests a negative year over year growth rate of 61.1%. The company is expected to announce its next quarterly earnings report on Wednesday, November 27th.

On average, analysts expect that Oramed Pharmaceuticals will report full year earnings of ($0.94) per share for the current year, with EPS estimates ranging from ($1.02) to ($0.88). For the next fiscal year, analysts expect that the business will report earnings of ($0.85) per share, with EPS estimates ranging from ($0.98) to ($0.61). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Oramed Pharmaceuticals.

ORMP has been the subject of a number of recent analyst reports. LADENBURG THALM/SH SH initiated coverage on shares of Oramed Pharmaceuticals in a report on Wednesday, September 11th. They issued a “buy” rating and a $7.00 price objective for the company. ValuEngine upgraded shares of Oramed Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, HC Wainwright set a $20.00 price objective on shares of Oramed Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, September 18th.

NASDAQ ORMP traded down $0.02 during midday trading on Tuesday, hitting $3.04. The company had a trading volume of 21,200 shares, compared to its average volume of 51,285. Oramed Pharmaceuticals has a twelve month low of $2.78 and a twelve month high of $4.50. The company has a market capitalization of $54.41 million, a PE ratio of -3.53 and a beta of 1.24. The firm has a 50-day moving average price of $3.15 and a 200-day moving average price of $3.32.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

In related news, Director Leonard Sank bought 25,000 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was acquired at an average cost of $2.92 per share, for a total transaction of $73,000.00. Following the purchase, the director now owns 364,999 shares in the company, valued at $1,065,797.08. The acquisition was disclosed in a filing with the SEC, which is available through this link. 20.50% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Jane Street Group LLC purchased a new stake in Oramed Pharmaceuticals during the 2nd quarter valued at $155,000. Renaissance Technologies LLC raised its stake in Oramed Pharmaceuticals by 50.5% during the 2nd quarter. Renaissance Technologies LLC now owns 158,098 shares of the biotechnology company’s stock valued at $568,000 after buying an additional 53,043 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in Oramed Pharmaceuticals by 1,137.7% during the 3rd quarter. Tower Research Capital LLC TRC now owns 18,491 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 16,997 shares during the last quarter. Institutional investors and hedge funds own 4.82% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes.

Recommended Story: Book Value Per Share – BVPS

Get a free copy of the Zacks research report on Oramed Pharmaceuticals (ORMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Oramed Pharmaceuticals (NASDAQ:ORMP)

Leave a Reply

Your email address will not be published. Required fields are marked *

*